Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies.
Salmen J, Neugebauer J, Fasching PA, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Fehm T, Mohrmann S, Loehberg CR, Hein A, Schulz-Wendtland R, Hartkopf AD, Brucker SY, Wallwiener D, Friese K, Hartmann A, Beckmann MW, Janni W, Rack B. Salmen J, et al. Among authors: mohrmann s. Breast Cancer Res Treat. 2014 Nov;148(1):143-51. doi: 10.1007/s10549-014-3130-4. Epub 2014 Sep 25. Breast Cancer Res Treat. 2014. PMID: 25253172
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.
Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C. Diallo-Danebrock R, et al. Among authors: mohrmann s. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97. doi: 10.1158/1078-0432.CCR-06-1842. Clin Cancer Res. 2007. PMID: 17255270 Clinical Trial.
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group. Gluz O, et al. Among authors: mohrmann s. Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3. Ann Oncol. 2008. PMID: 18174609 Free article. Clinical Trial.
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A. Gluz O, et al. Among authors: mohrmann s. Breast Cancer Res Treat. 2011 Apr;126(3):643-51. doi: 10.1007/s10549-011-1377-6. Epub 2011 Feb 12. Breast Cancer Res Treat. 2011. PMID: 21318601 Clinical Trial.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Schönherr A, Aivazova-Fuchs V, Annecke K, Jückstock J, Hepp P, Andergassen U, Augustin D, Simon W, Wischnik A, Mohrmann S, Salmen J, Zwingers T, Kiechle M, Harbeck N, Friese K, Janni W, Rack B. Schönherr A, et al. Among authors: mohrmann s. Breast Care (Basel). 2012 Aug;7(4):289-95. doi: 10.1159/000341384. Breast Care (Basel). 2012. PMID: 23904831 Free PMC article.
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N, Zacarias Föhrding L, Vay C, Hoffmann I, Kasprowicz NS, Hepp PG, Mohrmann S, Nitz U, Stresemann A, Krahn T, Henze T, Griebsch E, Raba K, Rox JM, Wenzel F, Sproll C, Janni W, Fehm T, Klein CA, Knoefel WT, Stoecklein NH. Fischer JC, et al. Among authors: mohrmann s. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16580-5. doi: 10.1073/pnas.1313594110. Epub 2013 Sep 24. Proc Natl Acad Sci U S A. 2013. PMID: 24065821 Free PMC article.
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Nitz U, et al. Among authors: mohrmann s. Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827128 Free article. Clinical Trial.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A. Erber R, et al. Among authors: mohrmann s. Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28. Breast Cancer Res Treat. 2015. PMID: 25721604 Clinical Trial.
61 results